Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity

  1. Kotaro Shirakawa
  2. Lan Wang
  3. Na Man
  4. Jasna Maksimoska
  5. Alexander W Sorum
  6. Hyung W Lim
  7. Intelly S Lee
  8. Tadahiro Shimazu
  9. John C Newman
  10. Sebastian Schröder
  11. Melanie Ott
  12. Ronen Marmorstein
  13. Jordan Meier
  14. Stephen Nimer
  15. Eric Verdin  Is a corresponding author
  1. Gladstone Institutes, United States
  2. University of Miami, United States
  3. University of Pennsylvania, United States
  4. National Cancer Institute, United States

Abstract

Salicylate and acetylsalicylic acid are potent and widely used anti-inflammatory drugs. They are thought to exert their therapeutic effects through multiple mechanisms, including the inhibition of cyclo-oxygenases, modulation of NF-κB activity, and direct activation of AMPK. However, the full spectrum of their activities is incompletely understood. Here we show that salicylate specifically inhibits CBP and p300 lysine acetyltransferase activity in vitro by direct competition with acetyl-Coenzyme A at the catalytic site. We used a chemical structure-similarity search to identify another anti-inflammatory drug, diflunisal, that inhibits p300 more potently than salicylate. At concentrations attainable in human plasma after oral administration, both salicylate and diflunisal blocked the acetylation of lysine residues on histone and non-histone proteins in cells. Finally, we found that diflunisal suppressed the growth of p300-dependent leukemia cell lines expressing AML1-ETO fusion protein in vitro and in vivo. These results highlight a novel epigenetic regulatory mechanism of action for salicylate and derivative drugs.

Article and author information

Author details

  1. Kotaro Shirakawa

    Gladstone Institutes, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Lan Wang

    University of Miami, Gables, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Na Man

    University of Miami, Gables, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Jasna Maksimoska

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Alexander W Sorum

    Chemical Biology Laboratory, National Cancer Institute, Frederick, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Hyung W Lim

    Gladstone Institutes, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Intelly S Lee

    Gladstone Institutes, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Tadahiro Shimazu

    Gladstone Institutes, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. John C Newman

    Gladstone Institutes, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Sebastian Schröder

    Gladstone Institutes, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Melanie Ott

    Gladstone Institutes, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Ronen Marmorstein

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Jordan Meier

    Chemical Biology Laboratory, National Cancer Institute, Frederick, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Stephen Nimer

    University of Miami, Gables, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Eric Verdin

    Gladstone Institutes, San Francisco, United States
    For correspondence
    everdin@gladstone.ucsf.edu
    Competing interests
    The authors declare that no competing interests exist.

Copyright

© 2016, Shirakawa et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,767
    views
  • 1,206
    downloads
  • 59
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kotaro Shirakawa
  2. Lan Wang
  3. Na Man
  4. Jasna Maksimoska
  5. Alexander W Sorum
  6. Hyung W Lim
  7. Intelly S Lee
  8. Tadahiro Shimazu
  9. John C Newman
  10. Sebastian Schröder
  11. Melanie Ott
  12. Ronen Marmorstein
  13. Jordan Meier
  14. Stephen Nimer
  15. Eric Verdin
(2016)
Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity
eLife 5:e11156.
https://doi.org/10.7554/eLife.11156

Share this article

https://doi.org/10.7554/eLife.11156

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark LaBarge
    Research Article

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.

    1. Cancer Biology
    Jae Hun Shin, Jooyoung Park ... Alfred LM Bothwell
    Research Article

    Metastasis is the leading cause of cancer-related mortality. Paneth cells provide stem cell niche factors in homeostatic conditions, but the underlying mechanisms of cancer stem cell niche development are unclear. Here, we report that Dickkopf-2 (DKK2) is essential for the generation of cancer cells with Paneth cell properties during colon cancer metastasis. Splenic injection of Dkk2 knockout (KO) cancer organoids into C57BL/6 mice resulted in a significant reduction of liver metastases. Transcriptome analysis showed reduction of Paneth cell markers such as lysozymes in KO organoids. Single-cell RNA sequencing analyses of murine metastasized colon cancer cells and patient samples identified the presence of lysozyme positive cells with Paneth cell properties including enhanced glycolysis. Further analyses of transcriptome and chromatin accessibility suggested hepatocyte nuclear factor 4 alpha (HNF4A) as a downstream target of DKK2. Chromatin immunoprecipitation followed by sequencing analysis revealed that HNF4A binds to the promoter region of Sox9, a well-known transcription factor for Paneth cell differentiation. In the liver metastatic foci, DKK2 knockout rescued HNF4A protein levels followed by reduction of lysozyme positive cancer cells. Taken together, DKK2-mediated reduction of HNF4A protein promotes the generation of lysozyme positive cancer cells with Paneth cell properties in the metastasized colon cancers.